Merck launches high-stakes trial of dual-action eye drug aiming to halt leading cause of blindness

The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year

India’s bioeconomy hits $165.7 billion as govt unveils fresh biopharma push

DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports

BioE3 policy accelerates India’s biomanufacturing ambitions with biofoundries, AI hubs & space biotech

Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors

Biocon Foundation, BeST Cluster and NCBS launch first BioWISE Cohort for postgraduate women students

Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship

Orca Bio’s Orca-T FDA review extended to July 2026

Merck completes acquisition of JSR Life Sciences’ chromatography business

Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing

Wockhardt’s breakthrough antibiotic Zaynich wins key regulatory nod in India

Shreehas Tambe appointed CEO & Managing Director of Biocon

Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited

AstraZeneca’s breakthrough COPD drug Tozorakimab slashes flare-ups in landmark Phase III trials

High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo

Semaglutide not a “Quick Fix”: Top docs urge holistic approach as drug goes off patent in India

They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.